12:00 AM
 | 
Feb 13, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Imetelstat: Completed Phase II enrollment

Geron completed enrollment of 166 patients with locally recurrent or metastatic breast cancer in an open-label Phase II trial comparing 300 mg/m 2 imetelstat on day 1 of a...

Read the full 123 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >